Philippe Laffont’s Quest Diagnostics DGX Stock Holding History

Philippe Laffont’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,251	Closed	-$347K	–	219
2019 Q4	$347K	Buy	+3,251	New	+$339K	﹤0.01%	283

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Philippe Laffont's DGX Position: Q1 2020 in Review

Philippe Laffont sold out of Quest Diagnostics (DGX) in Q1 2020, closing a stake of 3,251 shares — an estimated $347K sold.

Philippe Laffont first reported a position in DGX in Q4 2019 and held it in 1 quarter. The position peaked at $347K in Q4 2019. 714 funds tracked by Wall St. Rank hold DGX as of Q1 2020.

Philippe Laffont reported no remaining Quest Diagnostics position as of Q1 2020 after selling out during the quarter.
Philippe Laffont sold 3,251 Quest Diagnostics shares in Q1 2020, an estimated $347K.
Philippe Laffont first reported a position in Quest Diagnostics in Q4 2019 and held it in 1 quarter.
Philippe Laffont's Quest Diagnostics position peaked at $347K in Q4 2019.
714 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2020.

Based on Coatue Management's 13F filing for Q1 2020, filed 15 May 2020.